| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| death D28 | 1.02 [0.95, 1.10] | | < 1 | | 0% | 13 studies (13/-) | 27.2 % | some concern | low | moderate | crucial | - |
| death or transfer to ICU | 1.09 [0.99, 1.20] | | < 1 | | 0% | 1 study (1/-) | 4.0 % | NA | not evaluable | | crucial | - |
| deaths | 0.99 [0.94, 1.04] | | < 1 | | 0% | 50 studies (50/-) | 66.1 % | some concern | critical | moderate | crucial | - |
| deaths (time to event analysis only) | 0.98 [0.89, 1.07] | | < 1 | | 30% | 10 studies (10/-) | 67.0 % | some concern | low | moderate | crucial | - |
| clinical deterioration | 0.80 [0.61, 1.05] | | < 1 | | 1% | 10 studies (10/-) | 94.6 % | some concern | low | moderate | important | - |
| clinical improvement | 1.17 [0.95, 1.43] | | > 1 | | 56% | 15 studies (15/-) | 93.2 % | some concern | low | moderate | important | - |
| clinical improvement (14-day) | 1.06 [0.87, 1.31] | | > 1 | | 54% | 15 studies (15/-) | 72.2 % | some concern | low | moderate | important | - |
| clinical improvement (21-day) | 2.09 [0.04, 119.96] | | > 1 | | 0% | 1 study (1/-) | 63.7 % | NA | not evaluable | | important | - |
| clinical improvement (28-day) | 1.31 [0.97, 1.76] | | > 1 | | 66% | 6 studies (6/-) | 96.0 % | some concern | not evaluable | moderate | important | - |
| clinical improvement (7-day) | 1.29 [1.05, 1.60] | | > 1 | | 36% | 10 studies (10/-) | 99.1 % | some concern | low | moderate | important | - |
| clinical improvement (time to event analysis only) | 1.24 [1.05, 1.46] | | > 1 | | 47% | 8 studies (8/-) | 99.5 % | some concern | not evaluable | moderate | important | - |
| death or ventilation | 1.03 [0.93, 1.14] | | < 1 | | 63% | 4 studies (4/-) | 30.4 % | some concern | not evaluable | moderate | important | - |
| hospital discharge | 0.96 [0.85, 1.08] | | > 1 | | 69% | 7 studies (7/-) | 24.5 % | some concern | not evaluable | moderate | important | - |
| mechanical ventilation | 0.88 [0.69, 1.11] | | < 1 | | 42% | 17 studies (17/-) | 85.8 % | some concern | low | moderate | important | - |
| mechanical ventilation (time to event analysis only) | 0.06 [0.01, 0.83] | | < 1 | | 0% | 1 study (1/-) | 98.2 % | NA | not evaluable | | important | - |
| radiologic improvement (14-day) | 1.17 [0.42, 3.26] | | > 1 | | 16% | 3 studies (3/-) | 62.1 % | some concern | not evaluable | moderate | important | - |
| radiologic improvement (7-day) | 0.40 [0.02, 6.97] | | > 1 | | 77% | 3 studies (3/-) | 26.9 % | some concern | not evaluable | moderate | important | - |
| viral clearance | 1.35 [0.95, 1.92] | | > 1 | | 53% | 11 studies (11/-) | 95.1 % | some concern | low | moderate | important | - |
| viral clearance (time to event analysis only) | 1.12 [0.87, 1.44] | | > 1 | | 32% | 4 studies (4/-) | 80.3 % | some concern | not evaluable | moderate | important | - |
| viral clearance by day 14 | 0.99 [0.93, 1.06] | | > 1 | | 0% | 9 studies (9/-) | 40.4 % | some concern | not evaluable | moderate | important | - |
| viral clearance by day 7 | 1.50 [0.78, 2.89] | | > 1 | | 70% | 8 studies (8/-) | 88.5 % | some concern | not evaluable | moderate | important | - |
| ICU admission | 0.82 [0.55, 1.23] | | < 1 | | 36% | 9 studies (9/-) | 82.8 % | some concern | not evaluable | moderate | non important | - |
| recovery | 1.18 [1.02, 1.36] | | > 1 | | 0% | 4 studies (4/-) | 98.9 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| cardiac arrest | 1.92 [0.35, 10.49] | | < 1 | | 0% | 1 study (1/-) | 22.7 % | NA | not evaluable | | important | - |
| related SAE (TRSAE) | 1.24 [0.50, 3.11] | | < 1 | | 0% | 1 study (1/-) | 32.0 % | NA | not evaluable | | important | - |
| serious adverse events | 0.96 [0.75, 1.24] | | < 1 | | 0% | 16 studies (16/-) | 61.6 % | some concern | low | moderate | important | - |
| acute kidney injury | 1.18 [0.44, 3.18] | | < 1 | | 0% | 1 study (1/-) | 37.2 % | NA | not evaluable | | non important | - |
| adverse events | 1.72 [1.34, 2.23] | | < 1 | | 51% | 15 studies (15/-) | 0.0 % | some concern | critical | moderate | non important | - |
| arrhythmia | 0.91 [0.72, 1.15] | | < 1 | | 0% | 3 studies (3/-) | 78.1 % | some concern | not evaluable | moderate | non important | - |
| elevated liver enzymes | 3.48 [1.40, 8.64] | | < 1 | | 0% | 1 study (1/-) | 0.4 % | NA | not evaluable | | non important | - |
| long QT | 2.39 [0.24, 23.87] | | < 1 | | 80% | 2 studies (2/-) | 23.0 % | some concern | not evaluable | moderate | non important | - |
| renal impairment | 1.43 [1.00, 2.05] | | < 1 | | 0% | 2 studies (2/-) | 2.5 % | some concern | not evaluable | moderate | non important | - |
| severe adverse events | 1.00 [0.02, 51.70] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
AE of interest endpoints 00 |
| Thromboembolic events | 0.89 [0.31, 2.55] | | < 1 | | 0% | 1 study (1/-) | 58.6 % | NA | not evaluable | | non important | - |
